Euroz Hartleys Research Report | BOT: All Bark No Bite
Euroz Hartleys has published a research note on Botanix maintaining a price target of $0.80.
The report addresses President Trump’s recent executive order on drug pricing and concludes it will have “little to no impact” on BOT or Sofdra™.
